Assembly Biosciences Stock Today
| ASMB Stock | USD 13.86 0.60 4.15% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Assembly Biosciences is trading at 13.86 as of the 30th of January 2025, a 4.15 percent decrease since the beginning of the trading day. The stock's open price was 14.46. Assembly Biosciences has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on February 10, 2021, Representative Chris Jacobs of US Congress acquired under $15k worth of Assembly Biosciences's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of December 2010 | Category Healthcare | Classification Health Care |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. The company has 6.36 M outstanding shares of which 14.42 K shares are presently shorted by private and institutional investors with about 0.41 trading days to cover. More on Assembly Biosciences
Moving against Assembly Stock
| 0.37 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.32 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Assembly Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Jason Okazaki | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAssembly Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Assembly Biosciences' financial leverage. It provides some insight into what part of Assembly Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assembly Biosciences (ASMB) is traded on NASDAQ Exchange in USA. It is located in Two Tower Place, South San Francisco, CA, United States, 94080 and employs 65 people. Assembly Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 88.1 M. Assembly Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.36 M outstanding shares of which 14.42 K shares are presently shorted by private and institutional investors with about 0.41 trading days to cover.
Assembly Biosciences currently holds about 116.69 M in cash with 22.74 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.41.
Check Assembly Biosciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Assembly Biosciences is $88.1 Million. Assembly Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On February 10, 2021, Representative Chris Jacobs of US Congress acquired under $15k worth of Assembly Biosciences's common stock.
Check Assembly Ownership Details
Assembly Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 14.5 K | |
| State Street Corp | 2024-09-30 | 12.8 K | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 12.7 K | |
| Citadel Advisors Llc | 2024-09-30 | 12.7 K | |
| Marquette Asset Management Inc. | 2024-09-30 | 9 K | |
| Amundi | 2024-09-30 | 7.9 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 3.5 K | |
| Barclays Plc | 2024-09-30 | 3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.7 K | |
| Armistice Capital, Llc | 2024-09-30 | 354 K | |
| Vanguard Group Inc | 2024-09-30 | 200.5 K |
Assembly Biosciences Historical Income Statement
Assembly Stock Against Markets
Assembly Biosciences Corporate Management
| Nicole White | Chief Officer | Profile | |
| AO FRACP | CEO Director | Profile | |
| Adam Zlotnick | Chief CoFounder | Profile | |
| Amy CFA | Investor Consultant | Profile | |
| Uri MD | CoFounder Advisor | Profile | |
| Michele Anderson | Chief Officer | Profile |
Already Invested in Assembly Biosciences?
The danger of trading Assembly Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assembly Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assembly Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assembly Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.